Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is -13.33% lower on its value in year-to-date trading and has touched a low of $5.24 and a high of $22.11 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CPRX stock was last observed hovering at around $14.76 in the last trading session, with the day’s gains setting it 1.36% off its average median price target of $22.00 for the next 12 months. It is also 32.83% off the consensus price target high of $24.00 offered by 5 analysts, but current levels are -4.0% lower than the price target low of $15.50 for the same period.
Currently trading at $16.12, the stock is -16.05% and -8.47% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.91 million and changing 9.21% at the moment leaves the stock 32.67% off its SMA200. CPRX registered 190.97% gain for a year compared to 6-month gain of 62.50%.
The stock witnessed a -17.33% loss in the last 1 month and extending the period to 3 months gives it a 20.25%, and is -19.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.11% over the week and 7.22% over the month.
Catalyst Pharmaceuticals Inc. (CPRX) has around 76 employees, a market worth around $1.63B and $191.80M in sales. Current P/E ratio is 26.51 and Fwd P/E is 13.32. Profit margin for the company is 34.90%. Distance from 52-week low is 207.63% and -27.09% from its 52-week high. The company has generated returns on investments over the last 12 months (19.00%).
Catalyst Pharmaceuticals Inc. (CPRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Catalyst Pharmaceuticals Inc. (CPRX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.20, where 1 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Catalyst Pharmaceuticals Inc. is expected to release its quarterly report on 05/10/2023.The EPS is expected to shrink by -48.10% this year.
Catalyst Pharmaceuticals Inc. (CPRX) Top Institutional Holders
The shares outstanding are 103.32M, and float is at 97.66M with Short Float at 10.76%.
Catalyst Pharmaceuticals Inc. (CPRX) Insider Activity
A total of 82 insider transactions have happened at Catalyst Pharmaceuticals Inc. (CPRX) in the last six months, with sales accounting for 46 and purchases happening 36 times. The most recent transaction is an insider sale by INGENITO GARY,the company’sChief Medical Officer. SEC filings show that INGENITO GARY sold 5,918 shares of the company’s common stock on Dec 06 at a price of $16.85 per share for a total of $99718.0. Following the sale, the insider now owns 30802.0 shares.
Catalyst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Nov 23 that COELHO PHILIP H (Director) sold a total of 9,999 shares of the company’s common stock. The trade occurred on Nov 23 and was made at $17.45 per share for $0.17 million. Following the transaction, the insider now directly holds 0.15 million shares of the CPRX stock.
Still, SEC filings show that on Nov 23, Miller Steve (Chief Operating Officer) disposed off 20,000 shares at an average price of $17.34 for $0.35 million. The insider now directly holds 553,791 shares of Catalyst Pharmaceuticals Inc. (CPRX).
Catalyst Pharmaceuticals Inc. (CPRX): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 2.09% up over the past 12 months and Pfizer Inc. (PFE) that is -15.31% lower over the same period. Abbott Laboratories (ABT) is -10.57% down on the 1-year trading charts.